Autologous hematopoietic stem cell transplantation for type 1 diabetes.
In this review, we present (1) the scientific basis for the use of high-dose immunosuppression followed by autologous peripheral blood hematopoietic stem cell transplantation for newly diagnosed type 1 diabetes (T1D); (2) an update of the clinical and laboratory outcome of 20 patients transplanted at the University Hospital of the Ribeirão Preto Medical School, University of São Paulo, Brazil, and followed up to January/2008, including 4 relapses among 19 patients without previous ketoacidosis; (3) a commentary on criticisms to our article that appeared in four articles from the scientific literature; and (4) a discussion of the prospectives for cellular therapy for T1D.
Voltarelli
Júlio C
JC
Department of Clinical Medicine, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, Brazil. jcvoltar@fmrp.usp.br
Couri
Carlos E B
CE
Stracieri
Ana B P L
AB
Oliveira
Maria C
MC
Moraes
Daniela A
DA
Pieroni
Fabiano
F
Barros
George M N
GM
Madeira
Maria Isabel A
MI
Malmegrim
Kelen C R
KC
Foss-Freitas
Maria C
MC
Simões
Belinda P
BP
Foss
Milton C
MC
Squiers
Elizabeth
E
Burt
Richard K
RK
D000818:Animals; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000628:therapy*; D006402:Hematologic Diseases / Q000150:complications / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D051379:Mice; D008954:Models, Biological; D014182:Transplantation, Autologous